MAPK3 and prostate cancer: In one study, the activation of ADORA3 with the ADORA3 agonist N6-(3-iodobenzyl) adenosine-5′-n-methylureamine inhibited adenylate cyclase in AT6.1 rat prostate cancer cells and thus inhibited PKA-mediated ERK1/2 activation, leading to a reduction in prostate cancer cell proliferation [57].